Concurrent use of multiple PPIs offers no additional benefit and may increase the risk of adverse effects. If acid control is insufficient, the prescriber may consider dose adjustment or switching to a different class of medication rather than stacking PPIs.
Antacids containing calcium carbonate or magnesium hydroxide can be taken, but they should be spaced at least 2 hours apart from rabeprazole to avoid reduced absorption of the PPI.
When traveling, keep the medication in its original packaging, carry a copy of the prescription, and ensure you have enough tablets for the entire trip. Rabeprazole is not a controlled substance, so it generally passes customs without issue.
No specific diet is required, but patients are advised to avoid excessive caffeine, spicy foods, or fatty meals that can exacerbate reflux symptoms.
Both are PPIs, but rabeprazole has a slightly faster onset of action and may achieve greater acid suppression at equivalent doses. Clinical choice depends on patient response, tolerability, and prescriber preference.
Rabeprazole is classified as Category B3 in the UK; it should only be used during pregnancy when the expected benefits justify any potential risk to the fetus. Discuss alternatives and risks with your obstetrician.
In the UK, the 10 mg tablet commonly bears the imprint “R 10” and the 20 mg tablet “R 20.” Imprints may vary by manufacturer.
Long-term PPI therapy can modestly increase serum magnesium and decrease calcium absorption. Periodic monitoring is advisable for patients on extended treatment.
Rabeprazole can enhance the anticoagulant effect of warfarin, leading to a higher INR. Patients on warfarin should have their INR checked more frequently after initiating or adjusting rabeprazole therapy.
Tablets retain full potency for the duration indicated on the packaging, typically up to the expiry date, provided they are stored at room temperature and protected from moisture.
Rabeprazole is a prescription medication that contains the active ingredient rabeprazole sodium. It belongs to the proton-pump inhibitor (PPI) class of drugs, which are used to reduce the amount of acid produced by the stomach. In the United Kingdom, rabeprazole is authorised for use by the Medicines and Healthcare products Regulatory Agency (MHRA) and is available as a pill in strengths of 10 mg and 20 mg.
Rabeprazole sodium is a reversible, potassium-competitive inhibitor of the gastric H⁺/K⁺-ATPase enzyme-commonly known as the “proton pump”-located on the secretory surface of parietal cells in the stomach lining. By blocking this final step in gastric acid secretion, the drug:
Because the inhibition is reversible, normal acid production resumes after the drug is discontinued.
Rabeprazole is approved by the MHRA for the following indications in adult patients:
The medication is intended for adults; paediatric use is not routinely recommended unless specifically prescribed by a specialist.
These effects are usually transient and resolve without medical intervention. Patients should be advised to maintain adequate hydration if diarrhoea occurs.
Because PPIs share a common pathway of gastric pH alteration, any medication that relies on an acidic environment for absorption (e.g., ketoconazole, itraconazole, atazanavir) may have reduced bioavailability when taken with rabeprazole.
If a patient is uncertain about other medicines, supplements, or herbal products they are using, they should inform their prescriber before starting rabeprazole.
GERD or erosive oesophagitis:
20 mg once daily, taken before the first meal of the day.
Peptic ulcer treatment:
20 mg once daily for 4-8 weeks, generally taken before breakfast.
H. pylori eradication (triple therapy):
20 mg twice daily (morning and evening) together with clarithromycin and amoxicillin for 7-14 days, as directed by the prescriber.
NSAID-induced ulcer prophylaxis:
10 mg or 20 mg once daily, depending on the patient’s risk profile and the NSAID dose.
If a dose is missed, take it as soon as remembered provided it is at least 6 hours before the next scheduled dose. Do not double-dose.
Symptoms of overdose may include severe nausea, vomiting, dizziness, and drowsiness. Management is supportive; there is no specific antidote. Seek emergency medical care if overdose is suspected.
Long-term therapy (>12 months) should be reviewed regularly. Abrupt cessation after prolonged use may lead to rebound hyperacidity. A step-down approach-e.g., reducing the dose or switching to an on-demand regimen-can minimise this effect.
This article provides educational information about rabeprazole and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
